Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Roche Holding AGCHIX:ROZ +5.62%77 EV-to-EBITDA is 14.50 as of Jul. 24, 2026, which is 12% above its 10-year median of 12.98. GuruFocus rates CHIX:ROZ with a GF Score™ of 77/100 and a GF Value™ of CHF270.42 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 742 Drug Manufacturers companies, Roche Holding AG ranks worse than 53.64% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Roche Holding AG's enterprise value is CHF305,248 Mil.
Roche Holding AG's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was CHF21,050 Mil. Therefore, Roche Holding AG's EV-to-EBITDA for today is 14.50.
The historical rank and industry rank for Roche Holding AG's EV-to-EBITDA or its related term are showing as below:
CHIX:ROz'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 10.17 Med: 12.98 Max: 17.32
Current: 14.06
During the past 13 years, the highest EV-to-EBITDA of Roche Holding AG was 17.32. The lowest was 10.17. And the median was 12.98.
CHIX:ROz's EV-to-EBITDA is ranked worse than 53.64% of 742
companies
in the Drug Manufacturers industry
Industry Median: 12.96
vs CHIX:ROz: 14.06
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Roche Holding AG (CHIX:ROz) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Roche Holding AG's PE Ratio (TTM) for today is calculated as:
Roche Holding AG's share price for today is CHF357.20.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Roche Holding AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was CHF15.330.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Roche Holding AG's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:ROZ vs LLY, JNJ, ABBV: EV-to-EBITDA Comparison
For the Drug Manufacturers - General subindustry, Roche Holding AG's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Roche Holding AG EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Roche Holding AG's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Roche Holding AG's EV-to-EBITDA falls into.
Roche Holding AG's current Enterprise Value is CHF305,248 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Roche Holding AG's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was CHF21,050 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Roche Holding AG (CHIX:ROZ) has a EV-to-EBITDA of 14.50 as of Jul. 24, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Roche Holding AG. This is 12% above median its historical median of 12.98. Over the past decade, Roche Holding AG's EV-to-EBITDA has ranged from 10.17 to 17.32. According to the industry distribution chart, Roche Holding AG ranks #398 out of 742 companies in the Drug Manufacturers industry, placing it in the top 53.6%.
Is Roche Holding AG's EV-to-EBITDA too high?
Roche Holding AG's current EV-to-EBITDA of 14.50 is 12% above median its 10-year median of 12.98. Over the past 10 years, this metric has ranged from a low of 10.17 to a high of 17.32. The Drug Manufacturers industry median EV-to-EBITDA is 12.96. Roche Holding AG's value of 14.50 is 11.9% above this industry median. Based on the distribution chart, Roche Holding AG ranks #398 out of 742 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Roche Holding AG has a GF Score™ of 77/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Roche Holding AG's EV-to-EBITDA compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Roche Holding AG ranks #398 out of 742 companies for EV-to-EBITDA. This places Roche Holding AG in the lower half of its industry. The industry median EV-to-EBITDA is 12.96. Roche Holding AG's value of 14.50 is 11.9% above this benchmark. Historically, Roche Holding AG's own EV-to-EBITDA has ranged from 10.17 to 17.32 over the past decade. While the company's 10-year median is 12.98 vs. the industry median of 12.96, Roche Holding AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 12.96, based on 742 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Roche Holding AG's current EV-to-EBITDA of 14.50 is 11.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Roche Holding AG. For the Drug Manufacturers industry, the median EV-to-EBITDA is 12.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Roche Holding AG's current EV-to-EBITDA is 14.50, which is 12% above median its own 10-year median of 12.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Roche Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Roche Holding AG (CHIX:ROZ) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF270.42, compared to a current price of CHF357.20 — trading 32.1% above its estimated fair value. The current EV-to-EBITDA is 14.50, which is 12% above median its 10-year median of 12.98 and 11.9% above the Drug Manufacturers industry median of 12.96. Roche Holding AG's overall GF Score™ is 77/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Roche Holding AG (CHIX:ROZ), the current EV-to-EBITDA is 14.50 as of Jul. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Roche Holding AG (CHIX:ROZ) Overvalued in 2026?
Based on GuruFocus' analysis, Roche Holding AG stock appears to be overvalued.
The current stock price of CHF357.20 is trading 32.1% above its estimated GF Value™ of CHF270.42.
GuruFocus considers Roche Holding AG to be Significantly Overvalued.
Key valuation signals for CHIX:ROZ:
EV-to-EBITDA: 14.50 (12% above median its 10-year median of 12.98)
GF Value™: CHF270.42 vs. price of CHF357.20 (32.1% above fair value)
Industry Position: 11.9% above the Drug Manufacturers median (#398 of 742)
No single metric tells the full story. See the CHIX:ROZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 40% of pharmaceutical sales, and centralized and point-of-care diagnostics for two-thirds of diagnostic-related sales.
77GF Score
Get the complete analysis for CHIX:ROZ
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:ROZ has been successfully added to your 
